The Joint Commission Awards Bone Marrow Transplant Certification to the Blood Cancer Center at The Jewish Hospital – Mercy Health
The Blood Cancer Center at The Jewish Hospital – Mercy Health has earned The Joint Commission’s Gold Seal of Approval® for Bone Marrow Transplant Certification. James Essell, MD, hematologist-oncologist with OHC, serves as Medical Director of the Blood Cancer Center.
The Jewish Hospital’s Blood Cancer Center underwent a rigorous on-site review earlier this year. Joint Commission experts evaluated compliance with national disease-specific care standards as well as with bone marrow transplant-specific requirements. They also assessed clinical practice guidelines and performance measures.
Established in 2002 and awarded for a two-year period, The Joint Commission’s Disease-Specific Care Certification evaluates clinical programs across the continuum of care and addresses three core areas:
- compliance with consensus-based national standards
- effective use of evidence-based clinical practice guidelines to manage and optimize care
- an organized approach to performance measurement and improvement activities
“The Jewish Hospital’s Blood Cancer Center has demonstrated thoroughly a high level of care for patients with blood cancers,” said Patrick Phelan, executive director, Hospital Business Development, The Joint Commission. “We commend The Jewish Hospital for being a leader in bone marrow transplant care, providing a higher standard of service for blood cancer patients in its community.”
“The Blood Cancer Center team prides itself on providing its patients with the highest standard of care, coupled with immense compassion. The Jewish Hospital is pleased to receive Disease-Specific Care Certification from The Joint Commission, the premier health care quality improvement and accrediting body in the nation,” added said Pat Davis-Hagens, Mercy Health Central Market President and CEO. “The certification provides us with the framework to continue the culture of excellence we’ve built to serve those in our community.”
“The most recent data released by the Center for International Blood and Marrow Transplant Research (CIBMTR) shows that The Jewish Hospital Blood Cancer Center/OHC leads top cancer centers regionally and nationally in overall survival of adult blood and marrow transplant patients. We attribute this achievement to our patient-centered philosophy of care and will continue to strive for the best overall blood and marrow transplant outcomes in the future,” add Davis-Hagens.
Each year, thousands of people develop blood diseases, such as leukemia, Hodgkin’s disease, non-Hodgkin’s lymphoma and multiple myeloma that are treatable with blood stem cell or bone marrow transplants. OHC and The Jewish Hospital – Mercy Health is the Tri-State leader in blood cancers and has been performing bone marrow transplants since 1993. Currently, its team of skilled and compassionate professionals perform more than 100 blood and bone marrow transplants each year.